2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-19417A
    Wf-516 310392-94-0 98%
    Wf-516 is an inhibitor of 5-HT reuptake, and an antagonist of 5-HT1A and 5-HT2A receptors, with Ki of 5 nM and 40 nM for 5-HT1A receptor and 5-HT2A receptor in humans, respectively, and has potent antidepressant activity.
    Wf-516
  • HY-19489R
    (±)-Levomepromazine (Standard) 851-68-3 98%
    (±)-Levomepromazine ((±)-Methotrimeprazine) Standard is the analytical standard of (±)-Levomepromazine (HY-19489). This product is intended for research and analytical applications. (±)-Levomepromazine ((±)-Methotrimeprazine) is the racemate of Levomepromazine (HY-B1693).
    (±)-Levomepromazine (Standard)
  • HY-19518R
    Latanoprostene bunod (Standard) 860005-21-6
    Latanoprostene bunod (NCX116; LBN) (Standard) is the analytical standard of Latanoprostene bunod. This product is intended for research and analytical applications. Latanoprostene bunod is a nitric oxide-releasing prostaglandin F2α analog. Latanoprostene bunod is a prodrug that, upon instillation into the eye, is hydrolyzed by corneal esterases into two active metabolites: Latanoprost (HY-B0577) and NO. Latanoprost activates the prostaglandin FP receptor to increase the outflow of aqueous humor through the uveoscleral pathway. NO increases aqueous humor drainage through the trabecular meshwork pathway, achieving synergistic enhancement targeting the dual pathways of aqueous humor outflow. Latanoprostene bunod can be used in research related to open-angle glaucoma and ocular hypertension.
    Latanoprostene bunod (Standard)
  • HY-19532R
    ZM241385 (Standard) 139180-30-6 98%
    ZM241385 (Standard) is the analytical standard of ZM241385. This product is intended for research and analytical applications. ZM241385 is a potent, high affinity and selective adenosine A2a receptor (A2AR) antagonist with a Ki value of 1.4 nM.
    ZM241385 (Standard)
  • HY-19652A
    (S)-Oxybutynin hydrochloride 230949-16-3 98%
    (S)-Oxybutynin (Esoxybutynin) hydrochloride is a potent muscarinic receptor antagonist.
    (S)-Oxybutynin hydrochloride
  • HY-19927A
    DA-6886 monohydrochloride 1645260-76-9 98%
    DA-6886 is a 5-Hydroxytryptamine receptor 4 (5-HT4) agonist. DA-6886 induces relaxation of the rat oesophagus preparation in a 5-HT4 receptor antagonist-sensitive manner. The evaluation of DA-6886 in CHO cells expressing hERG channels reveals that it inhibits hERG channel current with an pIC50 value of 4.3, indicating that the compound is 1000-fold more selective for the 5-HT4 receptor over hERG channels. DA-6886 can be used in the study of constipated irritable bowel syndrome.
    DA-6886 monohydrochloride
  • HY-19945R
    DAA-1106 (Standard) 220551-92-8 98%
    DAA-1106 (Standard) is the analytical standard of DAA-1106. This product is intended for research and analytical applications. 0
    DAA-1106 (Standard)
  • HY-19960R
    BCTC (Standard) 393514-24-4 98%
    BCTC (Standard) is the analytical standard of BCTC. This product is intended for research and analytical applications. BCTC is an orally active current inhibitor of vanilloid receptor type 1 (VR1). BCTC is a transient receptor potential cation channel subfamily M member 8 (TRPM8) and transient receptor potential vanilloid 1 (TRPV1) antagonist. BCTC is an insulin sensitizer and secretor. BCTC has anticancer and analgesic effects.
    BCTC (Standard)
  • HY-204630
    NMDAR modulator 2 2311911-06-3
    NMDAR modulator 2 (comound 9062) is a NMDA receptor modulator that is modulator of NMDA receptor function. NMDAR modulator 2 can be used for the study of psychiatric disorders in which glutamatergic transmission is pathologically increased (e.g., treatment resistant depression).
    NMDAR modulator 2
  • HY-32329R
    Setiptiline (Standard) 57262-94-9
    Setiptiline (Standard) is the analytical standard of Setiptiline. This product is intended for research and analytical applications. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
    Setiptiline (Standard)
  • HY-32329S
    Setiptiline-d3 1795024-97-3 98%
    Setiptiline-d3 is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine.
    Setiptiline-d3
  • HY-32709S
    Telcagepant-d8 1132641-75-8 98%
    Telcagepant-d8 (MK-0974-d8) is deuterium labeled Telcagepant. Telcagepant (MK-0974) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist with Kis of 0.77 nM and 1.2 nM for human and rhesus CGRP receptors, respectively.
    Telcagepant-d8
  • HY-33009R
    AS057278 (Standard) 402-61-9
    AS057278 (Standard) is the analytical standard of AS057278. This product is intended for research and analytical applications. AS057278 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant non-peptidic D-amino acid oxidase (DAAO) inhibitor with an IC50 value of 0.91 μM and EC50 of 2.2-3.95 μM. AS057278 can normalize phencyclidine (PCP)-induced prepulse inhibition in mice. AS057278 can be used for researching schizophrenia.
    AS057278 (Standard)
  • HY-33549R
    α-Methyl-p-tyrosine (Standard) 658-48-0
    α-Methyl-p-tyrosine (Standard) is the analytical standard of α-Methyl-p-tyrosine. This product is intended for research and analytical applications. α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases.
    α-Methyl-p-tyrosine (Standard)
  • HY-401563
    5-HT2A antagonist 4 methanesulfonate 676116-04-4 98%
    5-HT2A antagonist 4 methanesulfonate (Example 29) is a dopamine D2 receptor and serotonin 5HT2A receptor antagonist. 5-HT2A antagonist 4 methanesulfonate can be used for the study of central nervous system diseases.
    5-HT2A antagonist 4 methanesulfonate
  • HY-40294R
    Indazole (Standard) 271-44-3
    Indazole (Standard) is the analytical standard of Indazole. This product is intended for research and analytical applications. Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
    Indazole (Standard)
  • HY-50098R
    Mardepodect (Standard) 898562-94-2 98%
    Mardepodect (Standard) is the analytical standard of Mardepodect. This product is intended for research and analytical applications. Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier.
    Mardepodect (Standard)
  • HY-50682A
    Azeliragon dihydrochloride 1284150-65-7 98%
    Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB).
    Azeliragon dihydrochloride
  • HY-50682R
    Azeliragon (Standard) 603148-36-3 98%
    Azeliragon (Standard) is the analytical standard of Azeliragon. This product is intended for research and analytical applications. Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
    Azeliragon (Standard)
  • HY-50722B
    NNC 55-0396 free base 357400-14-7 98%
    NNC 55-0396 free base is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396 free base
Cat. No. Product Name / Synonyms Application Reactivity